

REMARKS

Reconsideration of this application is requested in view of the amendments to the claims and the remarks presented herein.


The claims in the application are claims 1 to 6 and 14, 15 and 22 to 25, all other claims having been cancelled.

After the Examiner made a three way restriction requirement in the office action of June 13, 2003, the Examiner has now made a further restriction requirement of the groups I to VII as set forth in the present office action. The Examiner was of the opinion that the seven groups were patentably distinct and that Applicants may chose to elect a single invention by identifying another specific embodiment not listed in the groups listed by the Examiner.

Applicants respectfully traverse the Examiner's restriction requirement and ask that the Examiner examine the claims as amended which claims have been limited to those of group Formula (I)₃ and their method of use. It is believed that the present compounds and their use are all properly examined in the present application. The method of treatment claims have been for disorders of the central or peripheral nervous system with sub-claims directed to specific diseases falling within the scope thereof.

In view of the amendments to the claims and the above remarks, it is believed that the claims are now directed to a single invention properly examined together and a prompt examination on the merits is requested since the first two office actions were merely restriction requirements.

Respectfully submitted,
Muserlian, Lucas and Mercanti

A handwritten signature in dark ink, appearing to read 'Charles A. Muserlian', is written over a horizontal line.

Charles A. Muserlian, 19,683
Attorney for Applicants
Tel.# (212) 661-8000

CAM:ds
Enclosures